Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 14/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600101 | 0.90 | PIK3CB (0.51) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3588014 | 0.88 | PIK3CA (0.51) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3604836 | 0.81 | PIK3CB (0.57) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3592537 | 0.79 | PIK3CB (0.46) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3607310 | 0.79 | LMNA (0.46) | PIK3CBHTTPIK3CALMNAKMT2A | |
| SCHEMBL3613154 | 0.79 | PIK3CB (0.46) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3605489 | 0.77 | ALDH1A1 (0.43) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL17859942 | 0.76 | CYP1A2 (0.54) | PIK3CBHTTCRHBPCRHR2LMNA | |
| SCHEMBL3600075 | 0.75 | MTOR (0.67) | PIK3CBHTTPKMTSHRPIK3CA | |
| SCHEMBL3938069 | 0.74 | CYP1A2 (0.49) | PIK3CBHTTCRHBPCRHR2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | PIK3CB 9/4885HTT 3450/4885PKM 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.